TargetMol

Lisaftoclax

Product Code:
 
TAR-T10483
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10483-1mg1mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-5mg5mg£625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-1mL1 mL * 10 mM (in DMSO)£858.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-10mg10mg£867.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-25mg25mg£1,251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10483-100mg100mg£2,223.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lisaftoclax is a dual Bcl-2 and Bcl-xl inhibitor (IC50: 2 nM and 5.9 nM) with antitumor activity.
CAS:
2180923-05-9
Formula:
C45H48ClN7O8S
Molecular Weight:
882.42
Pathway:
Apoptosis
Purity:
0.9714
SMILES:
C(C1=C(CC2(CC1)CCC2)C3=CC=C(Cl)C=C3)N4CCN(CC4)C5=CC(OC=6C=C7C(=NC6)NC=C7)=C(C(NS(=O)(=O)C8=CC(N(=O)=O)=C(NC[C@H]9COCCO9)C=C8)=O)C=C5
Target:
BCL

References

1. WANG, Chia, et al. N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1.